Portal Instruments

About Portal Instruments

Portal Instruments, a medical device company established in 2012, is advancing the field of drug delivery for chronic diseases. The firm is currently a clinical-stage entity, indicating its products are undergoing human testing. Its core technology, a needle-free injection system, originated from research conducted at the Massachusetts Institute of Technology (MIT). The company was co-founded by CEO Patrick Anquetil, an entrepreneur with a Ph.D. from MIT, and Professor Ian Hunter, the Hatsopoulos Professor of Mechanical Engineering at MIT, whose work in bio-instrumentation and robotics laid the scientific groundwork for the company's platform. This foundational research at MIT's BioInstrumentation Laboratory focused on developing a controllable, needle-free method for administering medicine.

Portal Instruments is developing a device designed to administer biologic drugs without the use of needles, aiming to improve the experience for patients with chronic conditions who require frequent self-injections. The technology employs a computer-controlled linear actuator to propel a fine stream of medication—as thin as a human hair—through the skin. This method allows for the rapid, one-tenth-of-a-second administration of viscous drugs that are typically challenging to inject. The device is intended to be a reusable handheld applicator with single-use, disposable cartridges, separating the drug from the device itself. This system is also designed with connectivity in mind, featuring capabilities to automatically track injection history and transmit this data to a patient's healthcare provider, thereby enhancing adherence monitoring.

The company targets the large and growing biologics market, which includes treatments for chronic autoimmune diseases like rheumatoid arthritis and Crohn's disease. Its business model appears to be centered on partnerships with pharmaceutical companies, positioning its device as a delivery solution for their specific biologic drugs. This strategy allows for co-development and regulatory submissions tailored to a particular therapy. The company has secured Series C funding and counts institutional and strategic investors, including the pharmaceutical firm Sanofi, among its backers. While the device is not yet commercially available, it represents a significant effort to shift the paradigm of self-administered therapies from traditional needle-based methods to a digitally integrated, needle-free alternative.